Andalusian Agency for Health Technology Assessment, Emerging Technologies Observatory, Avd de la Innovación s/n, Edificio Renta Sevilla, Planta 2, 41020 Seville, Spain.
Vaccine. 2010 Jun 11;28(26):4328-34. doi: 10.1016/j.vaccine.2010.03.068. Epub 2010 Apr 18.
A systematic review was performed to assess the safety and immunogenicity of the prepandemic H5N1 influenza vaccines licensed so far. A bibliographic search according to the COSI protocol was carried out and 8 of 235 potentially relevant publications were selected. Quality assessment was defined with both CASP and Jadad checklists. Taken together, the results from the present systematic review suggest that the inactivated split-virion formulation that includes a low antigen dose (3.8 microg) and an oil-in-water emulsion-based adjuvant, represents the best option in the case of a pandemic, due to its antigen-sparing capacity and its favorable safety profile.
一项系统评价评估了迄今为止已获得许可的大流行性 H5N1 流感疫苗的安全性和免疫原性。根据 COSI 方案进行了文献检索，共筛选出 235 篇潜在相关文献中的 8 篇。采用 CASP 和 Jadad 清单进行质量评估。总的来说，本系统评价的结果表明，在大流行期间，包含低抗原剂量（3.8μg）和油包水乳剂佐剂的灭活分病毒制剂是最佳选择，因为它具有节省抗原的能力和良好的安全性。
